Clinical Trial Update: Risankizumab for Fibrostenotic Crohn's Disease Treatment [Phase 3]

View source ↗

Summary

A Phase 3 trial of risankizumab (Skyrizi) for fibrostenotic Crohn's disease is planned, with a not-yet-recruiting status; Crohn's disease and ulcerative colitis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Ulcerative Colitis

Drugs mentioned

• SKYRIZI (risankizumab-rzaa)

Snippet

Sponsor: First Affiliated Hospital of Wenzhou Medical University | Conditions: Crohn Disease, Crohn Disease and Ulcerative Colitis | Phase 3 | Status: NOT_YET_RECRUITING